Everest Medicines Appoints Wende Chen as Chief Commercial Ocer

May  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

SHANGHAI, China  and   NEW YORK,  May  10,  2019   (GLOBE NEWSWIRE) --  Everest Medicines, a biopharmaceutical company focused on developing and  commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and other  parts of Asia, today  announced the appointment of pharmaceutical industry  veteran Wende Chen as its Chief Commercial Ocer. Mr. Chen will also  serve  as an  operating partner for  CBC Group,  formerly  known  as  C-Bridge Capital, the company’s founding investor.


In his new  role, Mr. Chen  will establish and  execute commercialization strategies and plans   across Everest   Medicines’   portfolio   of  therapeutic products.  He  will lead  all aspects of global  sales, channel and  alliance  strategies and  manage commercial partnerships and opportunities.


“We are  delighted to  welcome Wende  to  the  team during  this  key period  in Everest Medicines rapid growth,” said Sean  Cao, interim CEO of Everest  Medicines. “He brings  a deep  knowledge of commercial operations including  market access, corporate affairs, and   product launches.  Bringing  on  board   an  executive  of  his  caliber   is  a  critical milestone for  the  company as we  advance our  product portfolio   through the  later stages of clinical development toward registration in China and other Asian markets.”


“I am very excited about the opportunity to join Everest  Medicines, which in a period  of under  two  years  has  built an  impressive portfolio  of late  stage therapeutic products that  will address high unmet needs in China and other  Asian markets,” said  Mr. Chen. “I look  forward   to   working   with  the   highly  experienced management team  as  the Company gears up for its anticipated rst product approval in China.”


Mr. Chen  brings  over  18  years  of leadership experience in the  global  pharmaceutical and  biotech industries.   Most   recently,  Mr.  Chen  served as  the  Vice  President  of Corporate Affairs , Market  Access and  Channel  Management at Roche  Pharma China, where  he  led  efforts to  improve  patient access to  Roche  products and  successfully achieved  national  reimbursement  drug   listing   for   Herceptin,    MabThera,  Avastin, Tarceva,  and  Zelboraf  in the  past two  years.  He also  played  an  instrumental role  in several key strategic initiatives, such  as using Direct-To-Patient specialty pharmacies to secure Roche product supply in the China market and launching the rst market access curriculum and  learning  and  development system in the  pharmaceutical industry  in China. Earlier in his career, he served as national sales director for Pzer  China, where in  nine  years  he  successfully grew  sales from  50M USD to  750M  USD and  launched several  new   products  that   achieved  the   largest  market  share  in  their   relevant therapeutic areas  in  China.  He  also   previously   served as  senior   vice  president at AstraZeneca,  where    he   led   commercial  operations   for   the   cardiovascular  and metabolic, gastric intestinal and  anesthesia, and  oncology business  units.  Mr. Chen holds  an Executive  Masters of Business Administration from  Hong Kong University of Science  and   Technology  and   a  Bachelor’s  degree  in  Medical   Clinic  from   Bengbu Medical College.


About Everest Medicines


Everest  is a CBC Group-backed biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that  address critical  unmet medical needs for patients in Greater  China and other  Asian markets. The management team of Everest  has  deep  expertise and an extensive track record  of high-quality clinical development, regulatory affairs,  CMC, business development and  operations both  in China and with leading  global pharmaceutical companies. For more  information, please visit its website at www.everestmedicines.com.


About CBC Group


CBC Group, formerly known as C-Bridge Capital, is a healthcare dedicated private equity rm, focused on growth and late stage, early stage and incubation opportunities across the  healthcare industry.  CBC Group is committed to supporting the  commercialization of  cutting-edge technologies  and  companies that  full unmet medical needs, thus continuously  improving   the   standard  and   quality   of  care   for  patients.  For  more information, please visit http://www.cbridgecap.com/#/indexEng.



Contacts:


Media in US and Europe: James Heins

Senior Vice President

ICR Healthcare (203) 856-2121 james.heins@icrinc.com



Media in China: Edmond  Lococo Senior Vice President

 


ICR Asia

+86 (10) 6583-7510

edmond.lococo@icrinc.com


info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.